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Abstract
Injuries to the postnatal skeleton are naturally repaired through successive steps
involving specific cell types in a process collectively termed “bone regeneration”.
Although complex, bone regeneration occurs through a series of well-orchestrated
stages wherein endogenous bone stem cells play a central role. In most situations,
bone regeneration is successful; however, there are instances when it fails and
creates non-healing injuries or fracture nonunion requiring surgical or therapeutic
interventions. Transplantation of adult or mesenchymal stem cells (MSCs) defined
by the International Society for Cell and Gene Therapy (ISCT) as CD105+CD90+CD73+CD45-CD34-CD14orCD11b-CD79αorCD19-HLA-DR- is being
investigated as an attractive therapy for bone regeneration throughout the world.
MSCs isolated from adipose tissue, adipose-derived stem cells (ADSCs), are
gaining increasing attention since this is the most abundant source of adult stem
cells and the isolation process for ADSCs is straightforward. Currently, there is
not a single Food and Drug Administration (FDA) approved ADSCs product for
bone regeneration. Although the safety of ADSCs is established from their usage
in numerous clinical trials, the bone-forming potential of ADSCs and MSCs, in
general, is highly controversial. Growing evidence suggests that the ISCT defined
phenotype may not represent bona fide osteoprogenitors. Transplantation of both
ADSCs and the CD105- sub-population of ADSCs has been reported to induce
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bone regeneration. Most notably, cells expressing other markers such as CD146,
AlphaV, CD200, PDPN, CD164, CXCR4, and PDGFRα have been shown to
represent osteogenic sub-population within ADSCs. Amongst other strategies to
improve the bone-forming ability of ADSCs, modulation of VEGF, TGF-β1 and
BMP signaling pathways of ADSCs has shown promising results. The U.S. FDA
reveals that 73% of Investigational New Drug applications for stem cell-based
products rely on CD105 expression as the “positive” marker for adult stem cells.
A concerted effort involving the scientific community, clinicians, industries, and
regulatory bodies to redefine ADSCs using powerful selection markers and
strategies to modulate signaling pathways of ADSCs will speed up the
therapeutic use of ADSCs for bone regeneration.
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Key Words: Mesenchymal stem cells; Adipose-derived stem cells; Endogenous stem cells;
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Core Tip: This review systematically examined current progress and future projections
of Adipose-derived Stem Cells (ADSCs) use in bone regeneration. Introduction
covered the regulatory aspects of stem cell therapy and scientific concerns regarding
stem cell use including ADSCs. We then analyze clinical and pre-clinical studies using
ADSCs for the treatment of bone defects. We also evaluate the current understanding
of ADSC’s surface receptors and therapeutic subpopulations. Overall, we conclude that
while mixed outcomes have been reported, a more rigorous definition of ADSCs,
selection of osteogenic subpopulations, and understanding of signaling pathways will
unleash ADSCs as a powerful tool in bone regeneration.

Citation: Le Q, Madhu V, Hart JM, Farber CR, Zunder ER, Dighe AS, Cui Q. Current evidence
on potential of adipose derived stem cells to enhance bone regeneration and future projection.
World J Stem Cells 2021; 13(9): 1248-1277
URL: https://www.wjgnet.com/1948-0210/full/v13/i9/1248.htm
DOI: https://dx.doi.org/10.4252/wjsc.v13.i9.1248

INTRODUCTION
Of the 7.9 million fractures sustained each year in the United States, 5% to 20% result
in non-union or delayed healings[1,2]. Since these fractures do not heal naturally, they
require therapeutic interventions. Transplantation of multipotent stem cells,
reportedly present in practically all postnatal tissues, is an attractive therapeutic
option. Mesenchymal stem cells (MSCs) isolated from bone marrow [bone marrowderived MSCs (BMMSCs)] are thought to be true, gold-standard osteoprogenitors[3].
To streamline investigations on MSCs, the International Society for Cell and Gene
Therapy (ISCT) defined MSCs in 2006 as cells satisfying the following three criteria:
Plastic adherent, CD105+CD90+CD73+CD45-CD34-CD14orCD11b-CD79αorCD19HLA-DR-, and possessing the ability to differentiate into osteoblasts, adipocytes, and
chondroblasts in vitro[4-6]. This remains the current definition of adult stem cells or
MSCs. This school of thought suggests that MSCs exist in all adult tissues and can give
rise to osteoblasts, chondrocytes, marrow stromal cells, and adipocytes. Accordingly,
the U.S. Food and Drug Administration (FDA) revealed that 73% of Investigational
New Drug applications for stem cell-based products rely on CD105 expression as the
“positive” marker for adult stem cells[7]. The optimal utilization of MSCs has been
prevented by the lack of ideal surface markers for selection and an incomplete
understanding of the heterogeneity of MSCs and factors governing their bone-forming
ability.
Clinical studies evaluating the exogenous addition of BMMSCs to enhance bone
repair in segmental defects, nonunion of the tibia, and tibial osteotomy have shown
increased healing rates[8-16]. However, several factors remain enigmatic for BMMSCs
therapies, including impure cell preparations, the significant numbers of cells required
to achieve satisfactory healing, supplementation of growth factors, the presence of
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other cell types at a higher frequency than MSCs, and incomplete fracture healing in
many patients, which suggest that more studies are required to fully understand MSCs
therapy[8-10,14]. These shortcomings in addition to the invasive nature of isolating
BMMSCs, their extremely low frequency in bone marrow, and the requirement of high
numbers of MSCs to achieve enhancement of bone healing, diminish the enthusiasm
for their therapeutic use.
In contrast, MSCs isolated from fat tissue [adipose-derived stem cells (ADSCs)] offer
the following advantages over BMMSCs: ADSCs can be isolated in large numbers
through a simple procedure, they possess higher proliferative capacity, their frequency
is 500 times higher than BMMSCs, they are resistant to senescence, and they retain
their differentiation potential for a longer period[17-25]. Given their clear clinical
advantages compared to BMMSCs, ADSCs are believed by many researchers to hold
great promises for implementation in regenerative medicine, specifically for the
treatment of orthopedic conditions. Nonetheless, the current body of research on this
topic yield confounding conclusions. The exact characterization of the osteoprogenitor
population within ADSCs remains in dispute. At the same time, ADSCs utilization
protocols vary greatly between different clinical and preclinical studies, which
themselves are inconclusive on the nature of ADSCs’ osteogenic capacity. Due to these
limitations, there has been no ADSC-based orthopedic product suitable for
widespread use. In this review, we attempt to capture the different aspects of current
research on ADSC in the hope to highlights the importance of ADSCs for bone
regeneration applications, current understanding of the subject, the obstacles facing
researchers, and possible strategies to further realize ADSCs’ potential as a therapeutic
tool.

REGULATORY ASPECTS OF STEM CELLS THERAPY
Although there is general agreement in the scientific community that stem cell therapy
holds great promise for bone repair and regenerative medicine applications, there is
not much agreement on the definition of adult stem cells. Moreover, several leading
experts in the field warn that the existing stem cell-based products are manufactured
without vigorous testing and are not backed up by strong scientific evidence. An
article titled “Clear up this stem-cell mess” published recently in Nature states that the
confusion about MSCs is making it easier for industries to sell unproven treatments
[26]. In agreement with this observation, another article in Cell Stem Cell comments that
clinical trials using MSCs have been conducted for more than a generation, but the
outcomes have fallen short of expectations[27].
A thorough understanding of the FDA guidelines is necessary for orthopedic
surgeons to decide whether the stem cell-based products that they are using or being
asked to use by industries are authenticated by the regulatory bodies. It is also
necessary to clarify that the FDA guidelines do not establish legally enforceable
responsibilities, but they describe FDA’s current thinking and therefore should be
viewed only as recommendations unless specific regulatory or statutory requirements
are cited. This puts a greater responsibility on clinicians and scientists to make sure
that the general public is aware of the effectiveness of stem cell therapy, and more
importantly, the patients receiving stem cell therapy are aware of the risk to benefit
ratio.
The current guidance issued by FDA is available under the docket number FDA2017-D-6146 (https://www.fda.gov/media/109176/download). Adult stem cell-based
products are regulated by the Center for Biologics Evaluation and Research, similar to
human cells, tissues, and cellular- and tissue-based products (HCT/Ps). These
regulations are provided by the FDA to HCT/P manufacturers, healthcare providers,
and FDA staff, under Title 21 of the Code of Federal Regulations (CFR) Part 1271.
These regulations explain the types of HCT/Ps that do not require premarket
approval; and the registration, manufacturing, and reporting steps that must be taken
to prevent the introduction, transmission, and spread of communicable disease by
these HCT/Ps: (1) The product is minimally manipulated; (2) It is intended for
homologous use and this is reflected by the labeling, advertising, and the
manufacturer’s objective intent; (3) The manufacture of the HCT/P does not involve
the combination of the cells or tissues with another article (except for water,
crystalloids, or a sterilizing, preserving, or storage agent, provided that these agents
are safe); (4) The product is not dependent upon the metabolic activity of living cells
for its primary function; and (5) If the product is dependent upon the metabolic
activity of living cells or has a systemic effect then it must be only for autologous use
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(cells isolated from the person transplanted back into the same person) or allogeneic
use in a first-degree or second-degree blood relative or for reproductive use.
In a cautionary observation, Skovrlj et al[28] reported that all five commercially
available cellular bone matrices for spine fusion, Osteocel Plus (NuVasive, San Diego,
CA, United States), Trinity Evolution (Orthofix, Lewisville, TX, United States),
Cellentra Viable Cell Bone Matrix (Biomet, Warsaw, IN, United States), AlloStem
(AlloSource, Centennial, CO, United States), and Ovation (Osiris Therapeutics,
Columbia, MD, United States), contain live, allogeneic MSCs but claim to meet the
FDA criteria under Section 361, 21 CFR Part 1271, and have not undergone FDA
premarket review. All of these products are composed of MSCs derived from freshly
procured cadaveric bone marrow, cadaveric adipose tissue, or chorion layer of the
placenta.
It is important to take notice of the fact that there is no stem cells-based product
currently approved by the FDA that can be used for bone tissue engineering purposes
or for the treatment of bone diseases. The list of all cell and gene therapy products
approved by the FDA can be found on FDA’s website:
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapyproducts/approved-cellular-and-gene-therapy-products. Thus, detailed investigation
on bone-forming potential of stem cells in vitro and in vivo followed by non-industry
sponsored clinical studies evaluating the efficacy of stem cells are required. Since
ADSCs can be isolated in a non-invasive procedure, in abundant numbers, for
autologous use, they offer a promising option for stem cell-based bone repair
therapies.

THE CLINICAL TRIALS USING ADSCS
To elucidate the possible clinical benefits of using ADSCs, many clinical trials have
been initiated. The clinical trials that will be used in our analysis were acquired from
Clinicaltrials.gov in December 2020 using the combination of keywords “Orthopedic
Disorder (Condition) - Adipose Stem Cells (Other terms)” and “Bone (Condition) Adipose-Derived Stem Cells (Other terms). The first combination of keywords
returned 74 registered trials while the second combination returned 17 trials.
Following content review, we eliminated any overlapping trials, trials that did not
directly involve orthopedic conditions, trials that did not include human patients, and
trials that did not explicitly state the use of ADSCs. This resulted in 70 trials being
included in this analysis. We found only four trials that addressed bone healing or
bone regeneration using ADSCs: NCT02140528, NCT04340284, NCT03678467, and
NCT03678467. While NCT03678467 is an ongoing trial, the results of the other three
are not published. We, therefore, searched PUBMED using the keywords “adipose
stem cells”, “orthopedic”, and “clinical” with the filter “Clinical Study” and found 10
relevant articles[29-38]. The general distribution of the 80 included clinical trials can be
seen in Figure 1. The outcomes of clinical trials on bone regeneration are summarized
in Table 1.
From the number of trials, it is clear that there is tremendous interest in ADSCs as a
therapeutic tool for a variety of orthopedic disorders. The earliest trials were started in
2008. However, the number of initiated trials has been on an upward trend since this
time. Moreover, only 37% of trials indicated as completed (total = 29). We will be
seeing a large number of trials ending in 2021 (total = 17), which will have important
implications for the field. The majority of the trials are in Phase 1 or 2, evaluating the
safety and initial efficacy of treatment with ADSC. Only 6 trials (8%) are in phase 3
and one is in phase 4. Of the 29 completed trials, 19 corresponding publications could
be found on PubMed using the National Clinical Trial registration number. Of these,
we will review in detail 10 publications directly investigating bone regeneration using
ADSCs.

SAFETY OF ADSCS ESTABLISHED IN CLINICAL TRIALS
In 2013, Pak et al[29] published the outcomes of long term follow up of 91 patients
undergoing injections of autologous ADSCs with platelet-rich plasma in various joints
to evaluate the safety of this treatment modality. Participants were observed for an
average of 16 mo. During this time, magnetic resonance imaging (MRI) evaluation
showed no evidence of neoplasm. Common adverse events included swelling of
injected joints, tenosynovitis, and tendonitis, all of which were either successfully
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Table 1 Summary of the clinical trials involving treatment of the bone defects using adipose-derived stem cells
Study duration and
n
length of follow up

Bone defect treated

Intervention

ADSCs source

ADSCs
number

Outcome

Ref.

Avascular necrosis of hip,
osteoarthritis of hip/knee/ankle,
spinal disc herniation

2009-2012, 30 mo

91

Intraarticular injection of SVF with
PRP

Autologous SVF from
abdominal tumescent
liposuction

10 mL of SVF

No evidence of neoplasm, no serious adverse events, common
adverse events (swelling of injected joints, tenosynovitis, and
tendonitis) were either successfully managed or self-limited,
established safety of ADSCs

Pak et al[29]

Upper arm fracture in elderly
patients (62-84 yr)

2012-2014, 6 mo

8

SVF seeded porous silicatedhydroxyapatite microgranules with
fibrin hydrogel implant

Autologous SVF from
abdominal tumescent
liposuction

800
microliters of
SVF

Evidence of osteogenesis at graft site; circumstantial evidence for
direct contribution of SVF cells to fracture healing

Saxer et al[30]

Large cranial defect

2008-2010, 12 mo

4

ADSCs-seeded β-tricalcium phosphate
implant

Autologous ADSC from
abdominal subcutaneous
liposuction

15 × 106 cells

Noted equivalence between newly generated tissue and native bone

Thesleff et al
[31]

Large cranial defect

2008-2016,
approximately 7 yr

5

ADSCs-seeded β-tricalcium phosphate
implant

Autologous ADSC from
abdominal subcutaneous
liposuction

15 × 106 cells

This study was long term follow up of Thesleff et al[31];
unsatisfactory long-term outcome with significant resorption

Thesleff et al
[32]

Cranio-maxillofacial hard-tissue
defects

2012-2014, up to 52
mo

13

ADSCs-seeded bioactive glass or βtricalcium phosphate scaffolds, at
times with recombinant hBMP-2

Autologous ADSC from
anterior abdominal wall
liposuction

Up to 160 × 10 Majority of patients achieved satisfactory clinical and radiographic
6
cells
results; three experienced significant resorptions of the ADSCs graft

Sándor et al
[33]

Long bone nonunion from bone
tumor resection or
pseudoarthrosis

2012-2014, 39 mo

6

ADSCs seeded decellularized bone
matrix

Subcutaneous autologous
ADSCs

Up to 200 ×
106 cells

50% of the patients achieved bone regeneration and union

Dufrane et al
[34]

Maxillary sinus floor elevation

2009-2015, 36 mo

10

SVF seeded β- tricalcium phosphate
implant

Autologous SVF from
20 × 106 cells
abdominal tumescent lipoaspiration

Experimental group exhibited significantly more bone healing
compared to control

Prins et al[35]

Alveolar cleft osteoplasty

2015-2016, 6 mo

10

Lateral ramus cortical bone plate with
ADSCs-mounted natural bovine bone
mineral

Autologous ADSCs from
buccal fat pad

1.0 × 106

No significant different in bone regeneration found between
experimental group and controls

Khojasteh et
al[36]

Mandibular fracture

2010-2015, 12 wk

20

Direct application of ADSCs

Autologous ADSCs

Unreported

Significantly more osteogenesis in ADSCs-treated group compared
to control

CastilloCardiel et al
[37]

Nonunion following subtalar
arthrodesis

2010-2016, 24 mo

140 ADSC-seeded partially demineralized
bone matrix

Allograft ADSCs

Unreported

Inferior bone union rate in ADSCs treated group compared to
autograft; equivalent clinical evaluations

Myerson et al
[38]

ADSCs: Adipose-derived stem cells; SVF: Stromal Vascular Fraction; PRP: Platelet-rich plasma.

managed or self-limited. Evaluation of pain using VAS suggested that most patients
experienced a significant reduction in pain three months post-operation.
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Figure 1 The clinical trials utilizing adipose-derived stem cells. The data were retrieved from clinical trials databases Clinicaltrials.gov and PUBMED. A:
Distribution of adipose-derived stem cells (ADSCs) clinical trials’ start and end dates. Clinical trials on bone regeneration with both identified start and end date are
represented in blue. All others are represented in orange; B: Distribution of ADSCs clinical trials’ status; C: Distribution of ADSCs clinical trials’ phase; D: Distribution
of ADSCs clinical trials’ targeted condition.

OUTCOMES OF CLINICAL TRIALS USING ADSCS FOR BONE REGENERATION
Saxer et al[30] published in 2016 the results of a study investigating the safety and
feasibility of a stromal vascular fraction (SVF) (construct in the treatment of proximal
humeral fractures in elderly patients. The construct was made from unexpanded and
undifferentiated human SVF derived from abdominal adipose tissue seeded onto a
silicated-hydroxyapatite and fibrin hydrogel scaffold. The construct was tested first on
male nude rats’ 6 mm critical-sized femoral defects. Compared to cell-free control, the
SVF-seeded construct was associated with significantly better mineralization and bone
volume. Histological staining also confirmed de novo osteogenesis and angiogenesis in
SVF-treated rats. The construct was subsequently tested on 8 patients aged 62-84 with
displaced, low-energy, proximal humerus fractures who were followed prospectively
for up to 12 mo post-surgery. The study confirmed that it was feasible for liposuction,
SVF isolation, graft manufacturing, and implantation to all be completed intraoperatively. The implant was deposited into the void space created following open
reduction and internal fixation. Over the follow-up period, the authors reported no
adverse reaction that could be linked to the graft. Pain evaluation via VAS showed no
lasting donor site pain and generally diminished operation site pain. Within one year
of the surgery, five out of eight patients had their plates removed, which provided the
opportunity for biopsy. The other three patients achieved subjective therapeutic goals
and declined plate removal. Histological and micro-CT analysis confirmed
osteogenesis at the graft site, either directly connected to or separated from the preexisting bone. Bone ossicles were also found in scaffold pores. The authors considered
these findings as circumstantial evidence for the direct contribution of SVF cells to
fracture healing.
In 2011, Thesleff et al[31] presented the results of treatment of 4 patients with
critical-size calvarial defects that underwent cranioplasty using grafts of ADSCs
seeded on beta-tricalcium phosphate granules. ADSCs were obtained autologously
from participants’ subcutaneous abdominal fat, isolated, and expanded over three
weeks. Participants were evaluated over a one-year follow-up period with computed
tomography (CT) scans, which showed ossification. Hounsfield Unit measurements
with CT scans showed approximate equivalence between normal bone and
regenerated tissue. No serious adverse event was reported. In 2017, the same research
group released the results of a 6-year follow-up on the same cohort of patients plus
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one more[32]. Unfortunately, the authors determined that the long-term outcomes of
ADSCs beta-TCP grafts for cranioplasty remained unsatisfactory. Among the five
patients who underwent the procedure, four needed revision surgeries at 0.9, 2.0, 2.2,
and 7.3 years following the original operation. Indications for re-operation included
infect, partial resorption of graft, complete resorption, and meningioma recurrence.
The grafts were then either removed and replaced with titanium, strengthened with
titanium mesh, or the patient underwent craniotomy in the case of meningioma. Only
one patient retained the original graft at the time of publication, but her skull X-ray
did show some level of graft resorption.
Sándor et al[33] in 2014 reported a case series involving 13 patients with craniomaxillofacial bone defects, three of the frontal sinuses, five of the cranial bones, three of the
mandibles, and two of the nasal septa. ADSCs from participants were harvested from
abdominal subcutaneous fat, expanded, and seeded on either bioactive glass or betatricalcium phosphate scaffolds. In the three mandible cases, rhBMP-2 was also added.
Follow-up periods ranged between 12 and 52 mo and showed satisfactory clinical and
radiographic results for patients with mandibular, frontal sinus, nasal septum defects.
Of the participants with cranial defects, two achieved clinically and radiographically
satisfactory ossifications, while the other three experienced significant resorptions of
the ADSC graft. One of the nasal septum defect patients resumed habitual nasal
picking during follow-up and needed graft removal.
Dufrane et al[34] published a study in 2015 describing the treatment of 6 patients
with long bone nonunion resulting from either bone malignancy or pseudoarthrosis.
These patients were treated using 3D bone grafts produced from subcutaneous
ADSCs, incubated in osteogenic media, and delivered using demineralized bone
matrix (DBM) without scaffolding. During the follow-up period of 47 mo, no acute
adverse events or tumorigenicity were reported, but there were two instances of
infection. Three out of six patients achieved bone regeneration and union.
Prins et al[35] published a study in 2016 evaluating the use of autologous SVF, rich
in ADSCs, seeded in calcium phosphate ceramics for maxillary sinus floor elevation.
SVF was obtained from the participants’ abdominal wall. A total of 10 participants
received either bilateral implants, with one side being SVF with ceramics and one side
being ceramics control or a unilateral implant of just SVF with ceramics. Follow-up
over three years showed no serious adverse event. Follow-up biopsy and micro-CT
showed active bone formation in the study arm with statistical differences in bone
volume over control, most notably in SVF with β-tricalcium phosphate ceramics
group.
In 2017, Khojasteh et al[36] published a phase I clinical trial following 7 patients with
alveolar clefts treated with autogenous bone osteoplasty in combination with buccal
fat pad derived ADSCs. Patients were divided into three treatment arms: Anterior iliac
crest (AIC) spongy bone with a collagen membrane, lateral ramus cortical bone plate
with ADSCs, and AIC spongy bone with ADSCs and collagen membrane. Results
indicated bone generation in all three experimental arms, weakest in the AIC only
group and strongest in the AIC with ADSCs group. However, the differences were not
statistically significant. No serious adverse event was reported.
Castillo-Cardiel et al[37] published in 2017 the results of a single-blind, randomized,
clinical trial involving 20 patients with mandibular angle fractures. Participants were
separated into two groups, a control group receiving fracture reduction only and a
stem cell treatment group receiving fracture reduction with application of ADSCs as
well. ADSCs were obtained from abdominal fat 24 h prior to the mandibular
procedure. Evaluation of bone regeneration over 12 wk showed statistically significant
improvement in ossification in the ADSC group compared to control.
In 2019, Myerson et al[38] published a multicenter, randomized controlled study to
compare safety and efficacy of ADSCs in subtalar arthrodesis (bone fusion of the
subtalar joint involving ankle bone and heel bone) with classic bone autograft. This
study included 140 patients enrolled in two study arms receiving either autologous
bone grafts or ADSCs. Autologous bone grafts were obtained from either the iliac crest
or the distal tibia. ADSCs were obtained autologously and deposited on partially
demineralized cancellous bone. Patients were followed up for over two years using
clinical scores such as AOFAS, SF-12, and FFI-R as well as radiographic evaluation for
the fusion of the subtalar joint. Imaging showed a lower rate of fusion in the ADSCs
group compared to autograft control. Nonetheless, both groups showed equivalent
clinical evaluations.
There are three clinical trials registered at Clinicaltrials.gov with no published
outcomes. NCT02140528 sought to evaluate the safety and efficacy of the injection of
allogeneic ADSCs on the healing of tibial fractures in 40 patients. Patients were
separated into two groups receiving either ADSCs injections or placebo. NCT04340284

WJSC

https://www.wjgnet.com

1254

September 26, 2021

Volume 13

Issue 9

Le Q et al. Adipose-derived stem cells for bone regeneration

is a retrospective report on the outcomes of 11 patients receiving fluoroscopic guided
percutaneous injections of SVF to the site of long bone nonunion. Healing was
evaluated over 12 mo using SF-12 and radiographic imaging. ADSCs were also
considered for Spinal Cord Injury, which was investigated in trial NCT02981576. This
study enrolled 14 participants separated into two arms receiving three intrathecal
injections of either autologous ADSCs or autologous bone marrow-derived MSCs.
Follow-up was done over 12 mo using ASIA impairment score as well as MRI
imaging.
Finally, clinical trial NCT03678467 is an open-label trial using an autologous,
anatomically shaped bone graft made from patients’ own ADSCs specifically for
patients’ mandible injury or deformity. The main goal of the study is to assess the
safety of the treatment. Six patients will be followed over 12 mo on the number of
adverse events, quality of life, and bone regeneration with CT scans.
In summary, a total of ten different studies conducted on total of 307 patients
suggest that the use of ADSCs is safe, but there is limited evidence that ADSCs can
significantly enhance bone regeneration.

RESERVATIONS ABOUT USING ADSCS FOR BONE REGENERATION
Considering the abundant availability of ADSCs and ease of their isolation, several
investigators have attempted to use ADSCs to enhance bone regeneration. These
studies were conducted using conventional preparations of ADSCs satisfying the ISCT
definition of adult stem cells or MSCs as CD105+CD90+CD73+CD45-CD34CD14orCD11b-CD79αorCD19-HLA-DR- cells. These studies suggested a limited
ability of ADSCs to induce bone formation or to enhance bone repair and raised
serious doubts about their therapeutic utility. The outcomes of the investigations are
summarized in this section.
Primary ADSCs failed to enhance bone healing, in defects created in rat calvaria and
sheep tibia[39,40]. In a canine maxillary alveolar cleft model, autografts induced
significantly higher bone formation than ADSCs-seeded on hydroxyapatite/betatricalcium phosphate scaffolds[41]. Godoy Zanicotti et al[42] used titanium surface as
the scaffold for delivery of ovine ADSCs to repair sheep femur epicondyle defects.
Histology and histomorphometry were used to evaluate the implants one month after
surgery. Using PKH26 cell-tracking dye, the authors were able to confirm the
persistence of ADSCs in the defect area at one month. Unfortunately, based on
histomorphometry results, no significant difference in regenerated bone tissue was
found among all experimental and control groups.
When human ADSCs (hADSCs) were implanted in immunodeficient animals, they
failed to induce any ectopic bone formation in 8 wk[43-46]. Spheroids of human bone
marrow-derived MSCs, but not hADSCs, could consistently induce ectopic bone
formation in immunodeficient mice[47]. Surprisingly, hADSCs did not survive in the
calvarial defects of nude mice after two weeks, although the recipient mice lacked T
cells[48]. While the theory of paracrine factors released by hADSCs in these two weeks
being sufficient for bone regeneration awaits more investigation, these data raise
questions about the usefulness of ADSCs for bone regeneration in healthy (immunocompetent) recipients. Corroborating this notion, ADSCs could not enhance calvarial
defect healing in immunocompetent rats[39].
Attempts by other investigators to improve the bone-forming ability of hADSCs, by
the addition of BMP-2 have also failed in a femoral defect model in T-cell deficient
nude rats[49]. This was proposed to be the consequence of the failure of hADSCs to
respond to BMP-2 in vitro[50]. In agreement with this finding Runyan et al[51] found
that recombinant human BMP-2 formed more bone than autologous ADSCs and
recombinant human BMP-2 in combination in a porcine model of the periosteal
envelope. Keibl et al[52] tested a fibrin scaffold embedded with ADSCs and BMP-2 in
the treatment of a non-critical size rat femur defect model. At two- and four weeks
post-treatment, the authors found no major difference among the groups indicating no
effect of BMP-2 on ADSCs potential and ADSCs alone could not induce any bone
repair. This questions the ability of ADSCs to induce bone formation and also their
ability to respond to BMP-2. Interestingly, this problem could be overcome by overexpressing BMP-2 and BMP-7 both in ADSCs. Qing et al[53] reported that only the BMP2/BMP-7 transduced ADSCs, but not non-transduced ADSCs, BMP-2 only ADSCs,
and BMP-7 only ADSCs, showed complete filling of the defect area in rat femur
defects. However, the combination of growth factors present in non-activated plateletrich plasma (nPRP), such as PDGF, TGF-b, bFGF, and VEGF, did not show any
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beneficial effect on ADSCs during rabbit calvarial defect healing[54]. There was little
difference between the nPRP-ADSCs group, ADSCs alone, and PRP alone in terms of
newly formed bone surface or volume.
Mazzoni et al[55] evaluated the osteogenic capacity of ADSCs on a hydroxyapatitecollagen hybrid scaffold in 50 patients undergoing malar augmentation. The authors
reported the follow-up over three years which showed implant stability and osteointegration but histological samples from patients revealed osteogenesis and mature
bone only in 70% of specimens.
Testing human stem cells in T-cell deficient animal models has been a regular
practice but that may not be the ideal way to test the potential of ADSCs. Recent
advances in the bone regeneration field suggest that certain T-cell subsets,
CD4+CD25+FoxP3+ Treg cells being a prominent one, are required for stem cells to
initiate the bone formation process. We believe that this could explain, at least
partially, the inability of ADSCs to induce bone formation in T-cell lacking mice and
rats.

PRECLINICAL STUDIES
Publications on preclinical studies utilizing ADSCs were obtained from OVID Medline
using the search keywords: “ADSCs”, “Stem Cells”, “Animals”, “Mesenchymal Stem
Cells”, “Tissue Engineering” and “bone regeneration”, which returned 90 studies. An
additional 14 studies were included from past collections by the researchers. After the
elimination of studies that either lacked in vivo experiments, lacked a focus on ADSCs,
or overlapped with other sections, 52 pre-clinical studies, investigating the boneforming ability of ADSCs using various animal models, are summarized in this section
and in Table 2.

COMPARISON OF ADSCS WITH SVF AND MSCS
Kang et al[56] compared canine MSCs from adipose tissue, bone marrow, umbilical
cord blood, and Wharton’s jelly in terms of their osteogenic potential in vitro and in
vivo. ADSCs showed the highest proliferation capacity at all passages in vitro.
Measured levels of ALP activity were highest in ADSC and umbilical cord bloodderived MSCs. When stem cells were mixed with β-TCP and implanted into the canine
segmental defects created in the radial diaphysis, comparable bone healing was
observed in all stem cells groups which were significantly higher than the scaffold
control group as determined by radiographic union, histology analysis, and the ratio
between newly formed bone over total defect size.
Toplu et al[57] created the bone defects on the bilateral zygomatic arches of 20 rats.
On one side, the defect was left for secondary healing and on the other side, SVF was
injected into the defect site. After 20 wk, Micro-CT analysis and histology confirmed a
significantly larger volume of newly formed bone in the SVF-injected side[57].

GROUP 1: PRE-DIFFERENTIATED ADSCS
Kim et al[58] treated rabbit 20 mm mid-diaphyseal ulna bone defects using SVF on a
PLGA scaffold. Animals were treated with scaffold alone, PLGA containing undifferentiated SVF cells, and PLGA with osteogenically induced SVF cells. Since the PLGAosteogenic SVF group showed significantly higher bone volume, the authors
concluded that osteogenic differentiation was necessary for optimal bone regeneration
by SVF. Osteogenically induced ADSCs-seeded coral scaffold showed statistically
significant more healing of the canine bilateral full-thickness parietal defect model in
comparison with control scaffold[59].
Investigators have also explored pre-differentiating ADSCs into endothelial lineage.
Shah et al[60] compared osteogenesis induced by ADSCs differentiated into osteogenic
lineage with those differentiated into endothelial lineage. Undifferentiated control
ADSCs and differentiated ADSCs were used to treat rats’ calvarial defects. The authors
were not able to find any statistically significant difference in osteogenesis and
angiogenesis among these groups. Sahar et al[61] also compared ADSCs differentiated
into endothelial lineage with ADSCs differentiated into osteogenic lineage when
implanted in a critical size rat calvarial defect model. The results showed that undiffer-
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Table 2 Summary of the preclinical studies involving bone regeneration induced by transplantation of adipose-derived stem cells
Animal model

Scaffold used

ADSCs per implant

Time
frame

Defect healing outcomes

Ref.

-Beagle Dogs; -Unilateral radial
segmental defect-10 mm

β-TCP/poly l-lactide-co-glycolide-co-ε-caprolactone
composite scaffold

1 × 106 canine ADSCs

20 wk

33.90 ± 4.31

Kang et al
[56]

Rat inguinal fat pad
derived SVF

20 wk

The average new bone growth in the experimental group was 1.1 mm,
significantly higher than control

Toplu et al
[57]

-Wistar albino rats; -Middle zygomatic No scaffold
arch defect; -3 mm wide
Group 1: Pre-differentiated ADSCs
-New Zealand white rabbits; -Middiaphysis of left ulna; -20 mm long

Porous polylactic glycolic acid scaffold

1 × 106 rabbit SVF cells

8 wk

Approximately 55%

Kim et al[58]

-Beagle dogs; -Parietal bone; -20 mm ×
20 mm full-thickness defect

Coral scaffold

60 × 106 of canine
ADSCs

24 wk

84.19 ± 6.45

Cui et al[59]

-Lewis rats; -Calvarial defect -8 mm
wide

Polylactic scaffold

0.1 × 106 rat ADSCs

8 wk

Coculture of endothelial- and osteoblast-induced ADSC showed no significant
improvement over undifferentiated cells

Shah et al[60]

-Lewis rats; -Calvarial defect; -8 mm
wide

Poly (D,L-Lactide) scaffold

0.1 × 106 rat ADSCs

8 wk

Osteogenic-induced ADSC generated 0.91 ± 0.65 mm3 new bone, significantly
higher than endothelial-induced ADSC

Sahar et al
[61]

Group 2: FGF, VEGF, PDGF, and ADSCs
-Osterix mCherry reporter mice; Closed transverse diaphysis fractures
of the right femur

No scaffold

0.3 × 106 wild-type
mice ADSCs

35 d

The experimental group induced significantly larger mineralized surface and bone
callus compared to cell-free and non-transduced controls.

Zhang et al
[62]

-Balb/c nude mice; -Parietal bone
defect; -4 mm wide

Whitlockite reinforced gelatin/heparin cryogels

1 × 106 human ADSCs

8 wk

> 16%

Kim et al[63]

-CD1 nude mice; -Parietal bone defect;
-4 mm wide

Coral scaffold

1.5 × 106 human
ADSCs

8 wk

95.40%

Behr et al[64]

-Sprague Dawley rats; -Distal femoral
cancellous bone -3.5 mm wide and 5
mm deep defect

Trimodal mesoporous bioactive glass scaffold

20 × 106 cell/mL until
saturation; rat ADSCs

8 wk

14.25 ± 3.57

Du et al[65]

-Nu/Nu J mice; -Parietal bone; -4 mm
wide

Polycaprolactone - fibrin scaffold containing heparinconjugated decellularized bone

0.2 × 106 human
ADSCs

12 wk

The experimental group induced a significantly larger new bone volume
compared to the control without PDGF

Rindone et al
[66]

-Sprague Dawley rats; -Full-thickness
parietal bone defect -5 mm wide

Polylactic glycolic acid scaffold

0.0025 × 106 human
ADSCs

8 wk

33.3 ± 29.0

Park et al[67]

-Chinese white rabbits; -Full-thickness
calvarial defects; -8 mm

Fibrin gel matrix

3 × 106 rabbit ADSCs

12 wk

Approximately 48

Lin et al[68]

-Japanese white rabbits; -Segmental
radial defect; -15 mm

Nano-hydroxyapatite/recombinant human-like
collagen/poly (lactic acid) scaffold

2 × 106 cells/ml; rabbit
ADSCs

12 wk

97.25 ± 2.06

Hao et al[69]

Group 3: BMP and ADSCs
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-Taiwan Lee-Sung minipigs; -Midshaft left femur defect; -30 mm long

Apatite coated poly (L-lactide-co-glycolide) scaffolds

100 × 106 cells/animal;
minipig ADSCs

12 wk

Experimental group’s new bone formation showed equivalent density and volume
compared to native bone and is significantly better than non-transduced control

Lin et al[70]

-CD-1 nude mice; -Full-thickness
parietal bone defect -3 mm wide

Porous poly(lactic-co- glycolic acid) scaffold

3 × 106 cells/mL;
ADSC from C57BL/6
mouse

6 wk

77%

Fan et al[71]

-Nude mice; -Parietal bone defect; -4
mm wide

Polylactic glycolic acid scaffold

5 × 105 human ADSCs

12 wk

83%

Li et al[72]

-Nude mice; -Subcutaneous
implantation

Porous poly(lactic-co- glycolic acid) scaffold

0.01 × 106 rat ADSCs

4 wk

Transduced ADSC construct induced more bone and vessel formation compared
to cell-free and non-transduced control

Weimin et al
[73]

-CD 1 nude mice; -Right parietal
bone defect; -4 mm wide

Polylactic glycolic acid scaffold

0.15 × 106 human
ADSCs

6 wk

Up to 100%

Levi et al[74]

-Athymic nude rat; -Mandible defect; 5 × 5 mm

Chitosan/chondroitin sulfate scaffold

0.25 × 106 ADSCs from
C57BL/6 mouse

8 wk

Approximately 43%

Fan et al[75]

Group 4: Genetically manipulated ADSCs
-BALB/c nude mice; -Subcutaneous
implantation

β-tricalcium phosphate scaffold

2 × 106 human ADSCs

8 wk

Approximately 30%

Wang et al
[76]

-Sprague Dawley rats; -Calvarial
defect; -8 mm wide and 1 mm thick

Poly (sebacoyl diglyceride) scaffold

Rat ADSCs

8 wk

50.53 ± 4.45

Xie et al[77]

Group 5: Engineered scaffolds and ADSCs
-C57BL6/J mice; -Mid femur defect; -2
mm

Strontium-substituted hydroxyapatite poly (γ-benzyl-lglutamate) scaffold

5 × 106 C57BL6/J mice
ADSCs

8 wk

Approximately 38%

Gao et al[78]

-Sprague Dawley rats; -Full-thickness
femur defect; -4 mm wide

NaB/polylactic glycolic acid scaffold

1 × 106 rat ADSCs

4 wk

ADSC-seeded poly lactic glycolic acid scaffold with 0.05% NaB induced the
highest bone density, compared to cell-free control and other concentration of NaB

Doğan et al
[79]

-Balb/c nude mice; -Cranium defect; 4 mm wide

SiRNA lipidoid nanoparticle immobilized on polydopamine
coated PLGA scaffold

1.0 × 106 human
ADSCs

8 wk

Approximately 75%

Shin et al[80]

-Sprague Dawley rats; -Calvarial
defect; -5 mm wide

Collagen-resveratrol scaffold

0.05 × 106 human
ADSCs

2 wk

Undifferentiated ADSC-seeded construct exhibited better osteogenesis compared
to controls and osteoinduced ADSC seeded scaffold

Wang et al
[81]

-Athymic nu/nu mice; -Subcutaneous
implantation

Alginate microspheres

0.5 × 106 rabbit ADSC

12 wk

Approximately 41%

Man et al[82]

1 × 106 human ADSCs

12 wk

Approximately 60%

Wang et al
[83]

-C57 black/DBA mice; -Supracondylar Hydrogel
right femur defect -0.9 mm wide

0.3 × 106 mice ADSC

8 wk

Approximately 50%

Deng et al
[84]

-Osteoporotic Sprague-Dawley female
rats; -Distal epiphysis left femur
defect; -3 mm wide

2 × 106 rat ADSCs

5 wk

Approximately 23%

Li et al[85]

Group 6: Manipulation of recipient host and ADSCs
-Sprague-Dawley rats; -Calvarial
defect; -7 mm wide
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Group 7: Allogeneic ADSCs
-New Zealand white rabbits; -Ulna
defect; -15 mm

Demineralized bone matrix

60 × 106 rabbit ADSCs

12 wk

Both allogeneic and autologous ADSC seeded construct induced almost complete
defect repair while cell-free control remained unrepaired

Gu et al[86]

-Sprague Dawley rats; -Ulna defect; -8
mm long

Demineralized bone matrix

60 × 106 rat ADSCs

24 wk

Radiographs and histology confirmed superior bone healing in the experimental
group compared to cell-free control

Wen et al[87]

-Beagle Dogs; -Parietal bone defect; -20 Coral scaffold
× 20 mm

60 × 106 of canine
ADSC

24 wk

Approximately 70%

Liu et al[88]

-Wistar rats; -Left radius defect; -4 mm Heterogeneous deproteinized bone
long

0.1 × 106 rat ADSCs

8 wk

Radiographs and histology confirmed improved healing in osteoinduced
ADSC/scaffold group compared to undifferentiated ADSC, cell-free, and blank
controls

Liu et al[89]

Group 8: Non-manipulated or unaltered ADSCs
Decellularized matrices
-CD1 nude mice; -Distal femur defect 3 mm

Human cancellous bone scaffold

0.5 × 106 human
ADSCs

8 wk

hADSCs-seeded scaffold induced significantly superior defect healing compared
to cell-free scaffold

Wagner et al
[90]

-C57BL/6 mice; -Calvarial defect; -4
mm wide

Extracellular matrix deposited on porcine small intestinal
submucosa

0.0025 × 106 of human
ADSCs

4 wk

21.77 ± 6.99

Zhang et al
[91]

-Institute of Cancer Research mice; Full-thickness parietal defect; -4 mm
wide

Decellularized tendon

1.0 × 106 human
ADSCs

8 wk

86%

Ko et al[92]

0.3 × 106 human
ADSCs

3 wk

ADSC-seeded scaffold resulted in a significantly smaller defect size than the
control

Wu et al[93]

-Sprague Dawley rats; -Two-wall
Amniotic membrane
periodontal intrabony defect; -2.6 × 2.0
× 2.0 mm
Ceramics
-Sheep; -Tibia; -3.2 cm long defect

Hydroxyapatite-based particle in a semi-solid milieu

56 × 106 human ADSCs

12 wk

The experimental group showed bridging and significantly better healing
compared to control

Ben-David et
al[94]

-New Zealand White rabbits; -Fullthickness proximal medial tibia defect;
-8 mm wide

Hydroxyapatite

0.2 × 106 rabbit ADSCs

8 wk

The new bone area was equivalent between seeded and unseeded scaffold;
however, ADSC seeded construct represented preferable histological
characteristics

Arrigoni et al
[95]

-New Zealand White rabbits; -Fullthickness proximal medial tibia; -8
mm in diameter

Hydroxyapatite

1.5 × 106 rabbit ADSCs

8 wk

ADSC-seeded scaffold exhibited better scaffold resorption than cell-free scaffold
and superior histological characteristics compared to all controls

De Girolamo
et al[96]

-Fisher 344 rats; -Calvarial defect; -5
mm wide

Hydroxyapatite

0.4 × 105 rat ADSCs

8 wk

16.88 ± 1.52

Xia et al[97]

-T and B cell-deficient NOD SCID
mice; -Subcutaneous implantation

Type I collagen (30%) and magnesium-enriched
hydroxyapatite

1 × 106 human ADSCs

8 wk

hADSC-seeded presented improved osteogenesis and angiogenesis compared to
cell-free scaffold control

Calabrese et
al[98]

-Miniature Pigs; -Mandibular defect -3
cm × 1 cm × 2 cm

Tri-calcium phosphate- poly (D,L-lactide-co-glycolide)
scaffolds

5 × 106 porcine ADSCs

12 wk

34.8 ± 4.80

Probst et al
[99]
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Bioactive glass
-Wistar rats; -Full-thickness calvarial
defect; -8 mm wide

Bioactive glass

0.5 × 106 rat ADSCs

12 wk

ADSC-seeded scaffold group exhibited significantly more bone repair and higher
bone density compared to blank control. ADSC construct’s result was equivalent
to that of autologous bone graft

Saçak et al
[100]

-Sprague Dawley rats; -Parietal bone
defect; -8 mm wide

Icariin doped bioactive glass

0.5 × 106 rat ADSCs

12 wk

The experimental group saw the complete repair of the defect while all controls
showed various degrees of incomplete healing; repair in the experimental group is
characterized by mature bone and complete scaffold resorption

Jing et al[101]

Polycaprolactone scaffold

0.05 × 106 human
ADSCs

8 wk

Both undifferentiated and osteo-induced ADSC-seeded scaffold resulted in
preferable histological features and higher expression of osteogenesis and
angiogenesis markers

Caetano et al
[102]

-Beagle dogs; -Tibial defects; -10 mm
wide

Activated platelet-rich plasma

1.0 × 106 human
ADSCs

6 wk

68.97 ± 0.91

Cruz et al
[103]

-F344 rat; -Calvarial defect; -5 mm
wide

Activated platelet-rich plasma

0.2 × 106 rat ADSCs

8 wk

95.60

Tajima et al
[104]

-New Zealand white rabbits; Calvarial defect; -10 mm wide

Hyaluronic acid-g-chitosan-g-poly (N-isopropylacrylamide)
embedded with biphasic calcium phosphate microparticles
and PRP

0.1 × 106 rabbit ADSCs

16 wk

The experimental group induced obvious significant bone formation and defect
bridging. Cell-free scaffold control showed negligible defect repair

Liao et al
[105]

-Sprague Dawley rats; -Parietal defect;
-5 mm wide

Multi-layered stacking of electrospun
polycaprolactone/gelatin membranes

0.006 × 106 rat ADSCs

12 wk

Up to 90%

Wan et al
[106]

-Balb/c nude mice; -Calvarial defect; 4 mm wide

1H,1H,2H,2H-per- fluorodecyl acrylate (97%) and glycidyl
methacrylate coated paper scaffold

1.0 × 106 cells/paper
human ADSCs

8 wk

92%

Park et al
[107]

Polymers
-Wistar rats; -Calvarial defect; -5 mm
wide

Platelet-rich plasma as carrier material

Hybrid materials

ADSCs: Adipose-derived stem cells; SVF: Stromal Vascular Fraction; PRP: Platelet-rich plasma.

entiated ADSC or osteogenic ADSC induced a significantly higher amount of bone
tissue than endothelial ADSCs group which was equivalent to acellular control.

GROUP 2: FGF, VEGF, PDGF, AND ADSCS
Modulation of the bone-forming ability of ADSCs by expressing genes of FGF, VEGF,
PDGF or by tethering these proteins to scaffolds has been reported. Zhang et al[62]
created bone defects in mouse femurs and injected control ADSCs or ADSCs
transduced with bFGF intramuscularly adjacent to the fracture site. While no
significant improvement was observed in the ADSCs group, improved bone healing
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was observed in the ADSCs-bFGF group. Interestingly, using GFP-assisted
observation, the authors identified that at day 21, only a very small fraction of the
originally implanted ADSCs remained in the healing callus. This supported the idea
that ADSCs’ role in bone healing is more reliant on its paracrine function rather than
direct cell replacement[62].
Kim et al[63] studied VEGF-transduced ADSCs for the treatment of mouse calvarial
bone defects. At week 8, microCT and histology revealed that groups with ADSCs
exhibited faster bone regeneration. In that, the VEFG overexpression group was found
to have significantly more bone healing. hADSCs pre-treated with VEGF also showed
beneficial effects. Behr et al[64] implanted hADSCs that were pre-treated with 2 µg
VEGF into critical-size calvarial defects of nude mice using coral scaffold. Quantification of defect filling at week 8 by microCT showed that the VEGFA treated ADSCs
group yielded significantly better bone regeneration than all other groups including
untreated ADSCs. VEGF is likely to have a direct effect on the differentiation of
ADSCs and it might also increase the bone healing rates indirectly by improving
angiogenesis during bone regeneration. Du et al[65] have reported that the bioactive
glass implant pre-vascularized in vitro for 7 d using endothelial cells and then seeded
with ADSCs was associated with enhanced angiogenesis and significantly more bone
regeneration in rat femur critical size defect compared to acellular scaffold and nonvascularized ADSC-seeded implant.
Similar to FGF and VEGF modulation, PDGF has been reported to improve the
osteogenic ability of ADSCs. Rindone et al[66] designed a scaffold in which PDGF-BB
was anchored using heparin-conjugation and simple electrostatic force. When
implanted in murine calvarial defects, the experimental group containing ADSCs and
PDGF-BB showed significantly higher bone formation compared to controls without
PDGF-BB.

GROUP 3: BMP
BMP-2 is FDA-approved for the treatment of bone injuries and is currently being
widely used to treat bone defects. It is known to govern osteogenic differentiation of
stem cells. Naturally, it has been the focus of investigation for improving the boneforming potential of ADSCs.
Park et al[67] investigated the ability of BMP-2 transduced ADSCs for the treatment
of full-thickness parietal bone defects in rats. Similar to control receiving no implant,
scaffold only group and scaffold with osteogenically induced ADSCs group showed
either no or incomplete filling. However, mice receiving BMP-2 transduced ADSCs
showed complete healing at week 8. Lin et al[68] compared bone formation induced by
BMSCs and ADSCs in rabbit calvarial defect model. BMSCs and ADSCs were
transduced with a BMP4-carrying-adenovirus vector and seeded on a fibrin gel
scaffold. Both transduced BMSC and ADSC groups showed a significantly higher
amount of newly regenerated bone tissue compared to their respective non-transduced
control. No difference was identified between transduced BMSC and transduced
ADSC groups. Hao et al[69] investigated the potential of BMP-2 overexpressing ADSCs
in a rabbit critical size radial segmental defect. The authors reported that animals
treated with transfected ADSCs-seeded scaffolds demonstrated recanalization of the
radial medulla, bone contour modeling, and scaffold degradation. No significant
defect repair was found in either scaffold only or scaffold with non-transfected ADSCs
groups.
Lin et al[70] overexpressed BMP-2 and VEGF genes in ADSCs and the resulting cells
were seeded on a PLGA scaffold which was implanted in a minipig massive segmental
left femoral defect model. Bone regeneration in the experimental group was observed
as early as two weeks post-procedure and progressively increased to complete union
at 12 wk. PET evaluation also revealed improved angiogenesis in the experimental
group compared to the control.
Strategies that promote BMP signaling in ADSCs have also been used successfully.
Fan et al[71] coated PLGA scaffolds with Phenamil and BMP-2 and then seeded the
scaffold with ADSCs. Phenamil is a derivative of the diuretic Amiloride, that acts as a
powerful stimulator of BMP-2 signaling. The authors hypothesized that using
Phenamil would allow optimal osteogenesis while reducing the needed BMP-2 dose to
avoid adverse effects. The construct was tested on a mouse calvarial bone defect
model. The authors reported that ADSCs-loaded scaffold treated with both Phenamil
and BMP-2 induced significantly improved bone regeneration compared to ADSCsloaded scaffold with BMP-2 alone group as measured by micro-CT. Li et al[72]
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transduced ADSCs to upregulate expression of BMP-2 and miR-148b using a
Cre/LoxP-based baculovirus hybrid before seeding onto gelatin-coated PLGA
scaffold. miR-148b is a miRNA identified for its osteogenic property when acting with
BMP-2. When this construct was used to treat critical-sized calvarial bone defects in
nude mice, the authors found that at 12 wk post-procedure, the experimental group
showed significantly improved bone healing compared to controls with either no
transduction, transduction with only miR-148b, or only BMP-2. Weimin et al[73]
expressed LIM mineralization protein 1 (LMP-1) and hypoxia-inducible factor 1 (HIF-1
α) genes in ADSCs to promote osteogenesis. LMP-1 was recognized as a positive
intracellular regulator of osteogenesis, upstream of BMP-2, while HIF-1a initiated
angiogenesis[41]. After lentiviral expression of genes in ADSCs, the resulting cells
were seeded onto a PLGA scaffold and tested on the dorsal subcutaneous pockets of
nude mice. Based on histological analysis, the authors claimed that there was more
neo-osteogenesis found in LMP-1 and HIF-1a expressing ADSCs than found in
controls.
Lentiviral delivery of shRNA to inhibit expression of Noggin, an inhibitor of BMP-2
signaling, in ADSCs has been shown to improve their osteogenic potential[74]. The
transduced ADSCs induced more rapid and complete healing of the calvaria defect in
nude mice in comparison with non-transduced ADSCs. BMP-2 addition and Noggin
inhibition together are known to further improve bone healing outcomes. Fan et al[75]
transfected ADSCs with lentivirus silencing the expression of noggin and loaded them
onto a chitosan and chondroitin sulfate scaffold, coated with apatite to ensure BMP-2
attachment and controlled release. The construct induced significantly more bone
repair in a rat mandibular defect model in comparison with blank scaffold, scaffold
with BMP-2, or scaffold with ADSCs (Nog-/-) at 8 wk.

GROUP 4: GENETICALLY MANIPULATED ADSCS
Wang et al[76] found that Prostaglandin G/H synthase 1 (PTGS1) is expressed in
ADSCs in response to TNF-α in inflammatory conditions and that PTGS1 knockout
ADSCs showed higher osteogenic potential. When PTSG1 knockout ADSCs were
mixed with Synthograft (Bicon), a commercial beta-tricalcium phosphate product, and
were transplanted into the dorsal subcutaneous tissue of mice, they induced
significantly more bone formation at week 8 compared to control[76]. Xie et al[77] used
lentivirus to transduce ADSCs to upregulate the expression of miR-135, a microRNA
recognized for its role in regulating osteogenesis. Transduced ADSCs were implanted
in rats’ critical-sized calvarial bone defect model. The authors observed almost
complete sealing of defect area when treated with miR-135 transduced ADSCs. All
other groups showed from nonexistent to incomplete filling of the defect.

GROUP 5: ENGINEERED SCAFFOLDS
Gao et al[78] developed a microcarrier from Strontium (Sr)-substituted hydroxyapatite,
which was found to release Sr ions, known activators of the Wnt/b-catenin pathway,
consistently at the right concentration. When these microcarriers were seeded with
ADSCs and implanted into mouse femur nonunion defect, they were found to
stimulate significantly more bone formation than control at 8 wk. Doğan et al[79]
incorporated boron into PLGA scaffold (NaB/PLGA) and seeded ADSCs onto it to test
this implant in a rat femur defect model. One month after implantation of ADSCNaB/PLGA, the ADSC-NaB/PLGA group showed the highest Hounsfield units which
represented superior bone regeneration compared to all other groups.
Shin et al[80] constructed a system in which siRNA lipidoid nanoparticles, designed
to target and silence the osteogenesis inhibitor guanine nucleotide-binding protein
alpha-stimulating activity polypeptide (GNAS), were immobilized on PLGA scaffolds,
and hADSCs were seeded onto this PLGA scaffold for treating mouse critical-sized
calvarial defect. The authors hypothesized that using this system, hADSCs could
undergo genetic modification and osteogenic induction after being seeded onto the
scaffold, eliminating the need for activation using culture-based protocols. At eight
weeks post-procedure, the experimental group showed significantly more bone
regeneration in comparison with no treatment control, construct without siRNA, and
construct with scrambled siRNA.
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Wang et al[81] combined collagen scaffold with Resveratrol (RSV), an antioxidant
with anti-inflammatory and osteogenic properties, and seeded ADSCs on the
construct. The authors reported that hADSCs-seeded collagen-RSV scaffold was the
most effective in bone regeneration in a rat calvaria defect model when compared with
other groups: collagen scaffold only, collagen scaffold with resveratrol, ADSCs seeded
collagen scaffold, and ADSCs seeded collagen scaffold with resveratrol, based on their
micro-CT results at 12 wk.
Man et al[82] evaluated the effect of PRP on the osteogenic potential of ADSCs
encapsulated in alginate microspheres. The microspheres were combined with 5%
PRP, 10% PRP or 15% PRP and injected subcutaneously in athymic nude mice. Only
groups receiving ADSC-Alginate with 10% and 15% PRP showed mineralization at 1
and 3 mo with the 15% PRP group showing a dose-dependent increase.

GROUP 6: MANIPULATION OF RECIPIENT HOST
Wang et al[83] used the hADSC-seeded PLGA constructs for the treatment of rat
critical-size calvarial defect and also evaluated the impact of locally injected
Alendronate (Aln), a bisphosphonate often used for the treatment of osteoporosis. At
12 wk the acellular groups (control and PLGA-Aln) showed limited bone formation
while both PLGA-ADSCs and PLGA-ADSC-Aln showed abundant mature neoosteogenesis. Complete bridging of the defect was observed only in the PLGA-ADSCAln group.
Deng et al[84] found that exendin-4 enhanced the ability of ADSC to induce bone
regeneration in a mouse femur metaphyseal defect model. Exendin-4 is a glucagon-like
peptide 1 receptor agonist previously recognized for its role in glycemic control,
control of bone resorption, and increased bone mass[84]. After creating the femur
metaphyseal defect, the authors planted hydrogels with ADSCs into the defect site
followed by daily intraperitoneal exendin-4. This experimental group was compared
with wild-type non-defective bone, defect bone without treatment, and defect bone
treated with ADSC only. The results of bone regeneration after 8 wk showed that this
experimental group exhibited significantly more repair than ADSCs only group as
well as the controls.
Li et al[85] reported that miR-214 targeted the Wnt pathway to favor adipogenesis in
ADSCs isolated from osteoporotic ovariectomized rats and this microRNA was found
at a high level in aged osteoporotic patients as well. Implantation of ADSCs genetically
manipulated to silence miR-214, but not unaltered ADSCs isolated from osteoporotic
rats, could lead to complete healing of critical size femoral metaphyseal defects in
ovariectomized rats when delivered using a gelatin scaffold.

GROUP 7: ALLOGENEIC ADSCS
The use of allogeneic stem cells is currently prohibited by FDA. However, there is
limited data available that allogeneic ADSCs can be as effective as autologous ADSCs
in rabbit, canine, and rat bone defect models.
Gu et al[86] investigated the osteogenic capacity of ADSCs-seeded DBM to treat
critical-sized ulna defects in a rabbit model. Micro-CT was used to compare three
experimental groups: Allogenic ADSC-seeded DBM, Autologous ADSC-seeded DBM,
and DBM only. The authors reported that both Allogenic and Autologous ADSC
groups showed bone formation that bridged the defect gap. DBM alone group, on the
other hand, did not show bridging of the defect but only loose fibrous tissue. Wen et al
[87] also used a DBM as a scaffold for allogeneic rat ADSCs to promote bone healing in
rat critical-sized ulnar bone defect model. At 24 wk, superior osteogenesis in defects
treated with ADSCs-DBM was recognized grossly and radiographically. ADSCs-DBM
treatment was also associated with significantly higher ulnar bone strength than those
treated with DBM only. Allogeneic ADSCs were shown to be as effective as
autologous ADSCs for the treatment of cranial critical-sized defects in canine models
as well[88]. There was no significant systemic immune reaction as measured by the
ratio of CD4/CD8 as well as serum levels of IL-2, IL-4, IL-10, IFN-g, and TGF-β1.
MicroCT evaluation showed equivalent bone regeneration between allogeneic and
autologous groups with both groups inducing significantly better healing than the
scaffold-only group. When GFP-positive ADSCs were implanted, they could still be
detected in osteocyte lacunae and bone matrix at 24 wk, pointing to their direct role in
osteogenesis.
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Liu et al[88] found that allogeneic ADSCs require pre-differentiation to be effective.
Undifferentiated allogeneic ADSCs failed to induce bone formation. They seeded
allogeneic ADSCs on heterogeneous deproteinized bone (HDB) and delivered the
construct for the treatment of critical-sized bone defects in a rat radius model[89]. The
authors investigated four groups: no implant, HDB implant only, non-induced ADSCs
seeded on HDB or osteogenically induced ADSCs on HDB scaffold. It was found that
at 8 wk, the group treated with osteogenic ADSCs on HDB showed evident bridging
with new bone completely filling the defect area. All other controls, on the other hand,
did not improve healing at 8 wk.

GROUP 8: SCAFFOLD TYPES USED FOR NON-MANIPULATED OR
UNALTERED ADSCS
To this end, many different materials have been experimented with in vitro and in vivo
in combination with ADSCs. Commonly used materials include decellularized tissues
used as matrix, ceramics, polymers, as well as hybrid materials.

Decellularized matrices
Various natural matrices such as human cancellous bone, porcine small intestinal
submucosa, bovine tendon, human amniotic membrane, have been used successfully,
after their decellularization, for delivery of unaltered ADSCs and this approach has
attained reasonable success in enhancing bone regeneration.
Wagner et al[90] investigated the combination of hADSCs and freeze-dried human
cancellous bone for treatment of femur critical-sized defect in rats. They optimized the
seeding density of ADSCs and found that a cell number of 250000 cells (84600
cells/100mm3) was optimal. At 4 wk, the authors observed a significant elevation of
bone regeneration in the ADSCs group compared to unseeded control. Zhang et al[91]
explored a scaffold made from the extracellular matrix (ECM) deposited on porcine
small intestinal submucosa (SIS). This porcine SIS construct was cultured with
osteoblasts to induce deposition of osteogenic ECM, followed by decellularization and
ADSCs seeding. The ADSCs-seeded ECM-SIS scaffold induced significantly more
healing of mouse critical-sized calvarial defects than SIS only, ECM-SIS, ADSC-SIS
groups. Ko et al[92] evaluated decellularized, bovine Achilles and neck tendons as the
scaffold for osteogenically induced hADSCs to evaluate bone regeneration in a mouse
calvarial bone defect model. The implant was placed in two layers into the calvarial
bone defects and its capacity for bone regeneration was evaluated. Results at 4 and 8
wk showed significantly better filling of the defect in the experimental group
compared to all controls. Wu et al[93] obtained amniotic membranes (AM) during
cesarian delivery, decellularized them, and co-cultured with ADSCs to initiate seeding.
This construct was used to treat two-wall periodontal bone defects in rats. CT imaging
of the defect 29 d after implantation showed a smaller defect volume in the ADSCsAM group compared to no treatment control, AM only, and ADSCs only.

Ceramics
Hydroxyapatite and β-tricalcium phosphate are the two most widely used matrices in
this group and have shown successful outcomes in supporting ADSCs-mediated bone
regeneration. ADSCs seeded and grown on hydroxyapatite-based mineral particles
could successfully treat full cortex segmental tibial defect in sheep[94]. Following
implantation of the ADSCs-seeded particles, statistically higher newly formed bone
volume was observed in the treatment group compared to the control. Arrigoni et al
[95] compared bone regeneration in a rabbit critical-sized tibial defect model mediated
by hydroxyapatite alone and ADSCs-seeded hydroxyapatite implant. The authors
reported that the ADSCs-seeded group displayed superior performance. de Girolamo
et al[96] also reported somewhat similar findings in the rabbit model when they used
autologous ADSCs seeded hydroxyapatite scaffold to treat full-thickness defects in
New Zealand rabbit’s proximal tibial epiphysis. At 8 wk, the authors reported that
there were no significant differences in defect filling and bone mineral density, but the
ADSCs-scaffold group induced the most mature bone that was quite similar to native
tissue. The structure of hydroxyapatite is reported to play an important role. Based on
in vitro results and data from the healing of the rats’ bilateral calvarial defects, the
micro-nano-hybrid structure, which is a hybrid of nanorod and microrod, was found
to be the most effective surface topography for the delivery of ADSCs[97]. Calabrese et
al[98] evaluated the ectopic bone formation induced by hADSC seeded on a collagen-
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hydroxyapatite scaffold through subcutaneous implantation in mice. The scaffolds
seeded with ADSCs exhibited faster hydroxyapatite formation and increased vascular
generation, both statistically significant in comparison with scaffold control.
Probst et al[99] examined the efficacy of pig ADSCs with tri-calcium phosphate poly
(lactic-co-glycolic) acid scaffold for regeneration of critical-sized mandibular bone
defects in minipigs. ADSCs were induced with an osteogenic medium prior to seeding.
MicroCT showed a significantly higher ratio of bone volume to total volume in the
ADSCs group in comparison with control but even in the test group, the regenerated
bone volume was only about one-third of the defect size.

Bioactive glass
Saçak et al[100] investigated bone regeneration in calvarial bone defect of mice using
ADSCs seeded bioactive glass. The authors divided the animals into four groups either
untreated, treated with autologous bone graft, treated with bioactive glass, or treated
with ADSC-seeded bioactive glass. Bone regeneration in the ADSC-seeded bioactive
glass group and autologous bone graft treatments were equivalent.
Jing et al[101] doped 45S5 Bioglass with Icariin, a flavonoid glucoside isolated from
the plant Herba Epimedii and then seeded the implant with ADSCs. Implantation of
the Icariin-doped, ADSC-seeded scaffold resulted in the complete repair of the rat
calvarial defect in 12 wk. Groups receiving no scaffold, Bioglass only, and ADSCseeded Bioglass without Icariin only exhibited partial repair. The authors reported that
when cultured with Icariin, ADSCs upregulate their expression of VEGF, thus
promoting angiogenesis which was the mechanism behind their enhanced osteogenic
potential.

Polymers
Caetano et al[102] evaluated the use of polycaprolactone, a semi-crystalline
biodegradable polymer, as a scaffold for human ADSCs to treat critical-size calvarial
bone defects in rats. They compared undifferentiated hADSCs with hADSCs cultured
in osteogenic conditions. The authors found osteoid tissue larger in size and more
organized in groups treated with both types of ADSCs. Immunohistochemical staining
revealed that the undifferentiated ADSCs group showed the highest percentage of
cells with BMP-2 expression. The two groups with ADSCs showed equivalent
angiogenesis, assessed via CD31 staining, which was significantly higher than no
ADSCs groups.

Platelet-rich plasma as carrier material
Cruz et al[103] evaluated the use of platelet-rich plasma activated with calcium
chloride as the carrier for ADSCs to treat 10 mm wide, beagle dog tibial bone defects.
Four defects were introduced in each animal. The defects were treated with clot, PRP
only, autogenous bone graft, or ADSCs-seeded PRP. Histological analysis showed that
the PRP-ADSCs group induced significantly more bone formation when compared to
control, autogenous bone graft, and PRP only.
Tajima et al[104] similarly explored activated PRP as the scaffold for delivering
ADSCs to rat calvarial defects. Based on micro-CT results at 4 and 8 wk following the
surgery, the authors found that ADSCs-seeded PRP demonstrated significantly larger
regenerated bone area and volume compared to treatment with ADSCs-seeded type 1
collagen, PRP only, type 1 collagen only, and PBS control. The authors also confirmed
that ADSCs transplanted by this manner differentiated into osteoblasts, by creating a
construct using GFP expressing ADSCs-seeded PRP and observing cells staining
positive for both GFP as well as osteocalcin.

Hybrid materials
Liao et al[105] used hyaluronic acid-g-chitosan-g-poly(N-isopropylacrylamide) (HACPN) embedded with biphasic calcium phosphate microparticles and PRP as the
organic matrix for delivery of rabbit ADSCs to critical-size cranial bone defects in
rabbits. This experimental implant induced significant bone formation, almost
completely covering the defect area while the control showed only negligible bone
formation at 16 wk.
Wan et al[106] designed a construct involving multi-layer stacking of three ADSCsseeded polycaprolactone/gelatin electro-spun membranes. The construct was
implanted into a model of calvarial defects in rats on bilateral parietal bones. The
authors reported that the ADSCs seeded multilayer membrane group showed
significantly more bone regeneration at higher density than those found in control and
scaffold-only groups.
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Park et al[107] evaluated a paper-based multi-layer scaffold for delivery of ADSCs to
a mouse calvarial defect model. Based on their in vitro results, the authors determined
that a scaffold of commercial weighing paper coated with 1H,1H,2H,2H-perfluorodecyl acrylate (97%) and glycidyl methacrylate was most suitable. The authors
compared two stacks of scaffolds only, two stacks of ADSCs-seeded scaffolds, three
stacks of alternating ADSCs-seeded scaffolds (A) and HUVEC seeded scaffolds (H),
and finally five stacks of alternating A-H-A-H-A scaffolds. All ADSCs seeded scaffolds
increased bone healing after 8 wk compared to the blank control and scaffold-only
groups. HUVEC-seeding did not show any statistically significant difference but there
was a trend of increased bone healing.

SURFACE RECEPTORS EXPRESSION-BASED SELECTION OF SUBPOPULATIONS OF ADSCS AS A RELIABLE STRATEGY TO IMPROVE THE
THERAPEUTIC POTENTIAL OF ADSCS
Since investigations utilizing ADSCs in their un-purified and unaltered form have
given mixed results, strategies to create ADSCs-based formulation that can enhance
bone healing, unambiguously and reliably are necessary. Therefore, the search for the
osteogenic sub-population of ADSCs has been initiated worldwide. Since a common
molecular marker for all osteogenic progenitors has not been discovered and the
precise identity of true skeletal stem cells, required for homeostasis and repair of the
postnatal skeleton, remains elusive, investigators have used various surface markers
for the selection of osteogenic sub-populations of ADSCs. The results of this investigation are summarized in this section and in Table 3.

CULTURED CELLS VS UNCULTURED SVF
Culture-expanded, horse ADSCs showed superior osteogenic ability when implanted
in nude rats than that induced by the uncultured SVF[108].

CD146
Interestingly, a mixture of two distinct FACS-purified hADSCs populations (CD146+
CD34- and CD146-CD34+) induced ectopic bone formation and also healed 60% of
calvarial defect created in immunodeficient mice[109-111]. When FACS-purified
CD146+CD34- cells were compared with unpurified SVF for their bone-forming ability
using the ectopic bone formation assay and in the calvarial defect model, cells showed
greater bone formation. Moreover, BMP2 treated cells showed more bone formation
but with a massive adipogenic response. Usage of Nel-1 in place of BMP2 avoided
adipogenesis to selectively promote only bone formation[110]. A study has shown that
both CD146+CD34 - and CD146-CD34+ subpopulations from hADSCs undergo trilineage differentiation and express adult stem cell markers CD105, CD90, CD73. CD34+
cells pre-cultured in an osteogenic medium for 3 d could induce bone formation in
calvarial defects[112].

CD90
FACS-purified CD90+ hADSCs, but not unpurified hADSCs, induced bone healing in
calvarial defects of nude mice[113]. However, when CD90+CD34 + hADSCs were
implanted in nude mice using a collagen sponge, they generated only adipose tissue
after 4 wk[114]. This indicates the relevance of CD34 expression. In another study,
mADSCs were FACS-purified into CD90+CD105-, CD90+CD105+, CD90-CD105-, and
CD90-CD105+ populations. Marker expression of cells in basal medium, in osteogenic
medium, and BMP2 transfected cells were determined. BMP2 transfection and
culturing in an osteogenic medium were found to decrease the expression of CD105
[115]. CD105low and CD90+ subpopulations were purified from hADSCs and compared
with each other for their osteogenic potential. CD90+ cells were found to be more
osteogenic compared to CD105low cells in vitro as measured by ALP, Alizarin Red
staining, and mRNA expression of Runx2, Ocn, Opn. When sorted cells were
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Table 3 Specific markers used for selection of sub-populations of adipose derived stem cells showing superior bone forming ability
Ref.

Marker

Study outcome and salient findings

CD146
James et
al[110]

CD146+CD34-CD45(Pericytes) + CD146CD34+CD45(Adventitial cells)

Intramuscular ectopic bone formation in SCID mice; FACS purified, human, pericytes + adventitial cells produced
significantly more ectopic bone formation than SVF; BMP2 enhanced osteogenic as well as adipogenic differentiation,
whereas Nel-1 promoted only bone formation when tested in ectopic bone formation assay; 250000 cells were
implanted intramuscularly in SCID mice for 4 wk using collagen sponge or DBX+ β-TCP + 3.5 -11.25 µg of BMP2 or 350
µg Nel-1

James et
al[109]

CD146+CD34-CD45(Pericytes) + CD146CD34+CD45(Adventitial cells)

Human pericytes + adventitial cells together make up around 40% of SVF from human lipoaspirate (60 patients tested)
both types representing around 20% and these numbers do not change with age, gender, or body mass index; FACS
purified, human, pericytes + adventitial cells induce significantly more healing in mouse calvarial defect than SVF;
250000 cells were implanted to critical size (3 mm) calvarial defect in SCID mice for 8 wk using PLGA

Meyers
CD146+CD34-CD45et al[112] (Pericytes) + CD146CD34+CD45(Adventitial cells)

It was feasible to purify human pericytes + adventitial cells using a multi-column approach of magnetic beads; Purified
pericytes + adventitial cells could enhance critical size (4 mm) calvarial defect created in SCID mice; 250000 cells were
implanted to critical size (4 mm) calvarial defect in SCID mice for 8 wk using PLGA

CD90
Chung
CD90+
et al[115]

CD90+ cells induced almost complete healing of critical size (4 mm) calvarial defect in nude mice compared to CD105
low
(approximately 75%), CD105high - (approximately 65%), and CD90- (40%) by micro-CT; Taken together CD90+ cells
are more osteogenic compared to CD105low cells; 150000 cells were implanted to critical size (4 mm) calvarial defect in
SCID mice for 8 wk using PLGA

Ferraro
CD90+CD34+
et al[113]

Implantation of human CD90+CD34+ ADSCs in nude mice resulted in the formation of only fat tissue surrounded by
loose connective tissue; 250000 cells were implanted subcutaneously in nude mice for 4 wk using a collagen sponge

CD105
Levi et al CD105low
[120]

FACS-sorted, human, CD105low sub-population of ADSCs significantly enhanced bone regeneration (> 95%) in critical
size (4 mm) calvarial defect in CD1-nude mice compared to CD105high (approximately 40%) and unsorted ADSCs (50%60%); Knockdown of CD105 in ADSCs (shCD105) resulted in improving their ability to induce bone formation (> 60%)
compared to ADSCs transfected with control shRNA (30%); 150000 cells were implanted to critical size (4 mm) calvarial
defect in nude mice for 8 wk using PLGA-HA

Madhu
CD105+CD34-; CD105
et al[123] + CD34+; CD105-CD34
+
; CD105-CD34-

FACS-purified, mouse, CD105+CD34− ADSCs that responded maximally to BMPs in vitro failed to induce ectopic bone
formation upon their sub cutaneous implantation immunocompetent syngeneic mice; FACS-purified CD105-CD34ADSCs responded the least to BMPs in vitro. A bone marrow-derived, clonal, osteoprogenitor population showing the
similar phenotype of CD105-CD34- induced robust bone formation; OM preconditioned 1 × 106 cells were implanted
subcutaneously in Balb/c mice for 4 wk using Matrigel

Chan et
al[128]

AlphaV+CD200+
CD105-D90-

Mouse skeletal stem cells that give rise to bone were identified as AlphaV+CD200+CD105-D90- cells and were present in
the femoral growth plate; They were not present in adipose tissue; however, when a collagen sponge loaded with BMP2 was implanted in adipose tissue, the authors reported de novo formation of AlphaV+CD200+CD105-D90- cells in the
adipose tissue; Subcutaneous implantation of 10 µg BMP2+ Collagen Sponge in nude mice for 4 wk

Chan et
al[131]

PDPN+CD164+CD73+
CD146-

The human counterpart of mSSC was discovered and was found to be of phenotype PDPN+ CD164+CD73+ CD146-;
Human adipose stroma did not naturally contain these cells but when it was mixed with BMP-2 and injected subcutaneously it led to skeletal reprogramming and induced formation of PDPN+ CD164+CD73+ CD146- human skeletal
stem cells; 10 × 106 cells with 10 µg BMP2 + Matrigel were subcutaneously implanted in nude mice for 4 wk

CXCR4
Xu et al
[133]

CXCR4+

CD146+CD34-CD45- cells were FACS-purified from hard (human periosteum) and soft (adipose and dermal tissue).
Cells isolated from hard tissue but not the soft tissues showed a strikingly high tendency for skeletogenesis; This
corresponded to high CXCR4 signaling in periosteal cells; Inhibition of CXCR4 signaling abrogated bone-forming
potential of CD146+CD34-CD45- periosteal cells; CXCR4+ cells from soft tissue (adipose) derived CD146+CD34-CD45cells represented osteoblastic/non-adipocytic precursor cells; 1 × 106 cells were implanted intramuscularly in nude
mice for 4 wk using DBM putty

PDGFRα
Wang et
al[134]

PDGFRα+

Lineage tracing using PDGFRα reporter mice showed that PDGFRα expression marks different sub-populations in the
adipose tissue; PDGFRα+ and PDGFRα− fractions both are multipotent progenitor cells, however, PDGFRα+ ADSCsderived ectopic implants ossify to a greater degree than PDGFRα− cell fractions; 1 × 106 PDGFRα+ or PDGFRα- cells
were implanted intramuscularly in nude mice for 8 wk using HA-β-TCP; Or Subcutaneous implantation of 2.5 µg
BMP2 + Matrigel into the inguinal fat pad of PDGFRα+ -CreER for 8 wk

ADSC: Adipose-derived stem cells; FACS: Fluorescence-activated cell sorting; SCID: Severe combined immunodeficiency; BMP: Bone morphogenetic
protein; TCP: Tricalcium phosphate; PLGA: Polylactic glycolic acid; HA: Hydroxyapatite; DBM: Demineralized bone matrix.

implanted into calvarial defects of nude mice, CD90+ cells showed more bone
formation[113].
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CD105, TGF-Β1 SIGNALING AND BMP-RESPONSIVENESS
While ADSCs have been conventionally characterized by positive expression of CD105
[39,40,59,116,117], many groups have also observed considerable amounts of
phenotypic variability within ADSCs during in vitro expansion[118,119]. Our group
and other laboratories are actively investigating the role of CD105 in determining the
osteogenic potential of ADSCs. CD105 is the co-receptor of the TGF-β1 signaling
pathway and is known to enhance signaling of the main receptors Alk1 and Alk5
through phosphorylation of the downstream mediators - Smads2/3.
It has been shown that FACs-purified CD105low hADSCs possess more osteogenic
differentiation potential than CD105high and unsorted cells in vitro, and also show
decreased TGF-β1 and Smad2 phosphorylation. Treatment with TGF-β1 significantly
reduces the osteogenic differentiation of CD105low ADSCs in vitro. In contrast,
treatment with the Alk5 inhibitor enhances osteogenic differentiation. Moreover,
CD105 knockdown promoted the bone-forming potential of ADSCs in immunodeficient animals in vivo[120-122].
We FACS-purified 4 different sub-populations of mADSCs; CD105+CD34-, CD105+
CD34+, CD105-CD34+ and CD105-CD34- and tested their BMP-responsiveness in vitro.
Only CD105+CD34- cells, showing the classical MSCs phenotype, responded to BMPs
while others did not show significant response. We hypothesized that the ADSCs
population maximally responding to BMPs in vitro would possess the ability to induce
bone formation, and therefore investigated the bone-forming potential of CD105+CD34
ADSCs in immunocompetent mice. Our hypothesis was clearly refuted and CD105+
CD34- ADSCs could not induce any bone formation[123]. Although we did not test the
bone-forming ability of other three FACS-purified populations in that study, we found
that bone marrow-derived D1 osteoprogenitor cells isolated from the same Balb/c
mouse strain, did not express CD105 and did not respond to BMPs in vitro, but showed
robust ability to induce bone formation[123,124]. Data from our group and others
suggest that CD105- population represents true osteoprogenitors and inhibition of
TGF-β1 signaling can improve the bone-forming ability of ADSCs. However, the boneforming ability of CD105- ADSCS is not yet established in immunocompetent hosts.
FACS purified CD105- human bone marrow-derived MSCs showed superior
osteogenic efficacy when compared to CD105+ cells in vitro. In critical-size defects
created in the tibia of canine, CD105- MSCs implantation led to superior bone healing
with complete bone remodeling, while CD105+ MSCs implants failed to remodel
resulting in the defect site filled with fibrocartilaginous tissue[125]. In sum, these
studies showed that CD105- cells have more osteogenic potential in vitro as well as in
vivo.
We have shown that simultaneously inhibiting TGF and BMP signaling pathways
by using small chemical inhibitors induces neuronal differentiation of hADSCs in vitro
and neurite outgrowth in vivo[126]. Previously this was demonstrated in ESCs and
iPSCs, but not in adult ADSCs. It is well established that activin/nodal signaling
contributes to the maintenance of pluripotency of hESCs. Activin/nodal/TGF-β and
BMP pathways naturally antagonize each other because they compete for a common
signal transducer Smad4. Inhibition of activin/nodal/ TGF-β signaling results in
trophoblast differentiation, similar to induction of trophoblast differentiation by BMP4[127]. These findings reveal the crucial roles of TGF-β and BMP signaling in deciding
the fate of ADSCs.
In a recent discovery, the phenotype of mouse skeletal cells (mSSC) has been
described as the CD45-Tier119-Tie2-AlphaV+Thy-6C3-CD105-CD200+ cells which were
isolated from femoral growth plates of the mice[128]. These CD105- cells were able to
form bone in vivo when implanted beneath the kidney capsule of T-cell deficient mice.
Surprisingly, these cells were not efficiently engrafted, suggesting their requirement
for a supportive niche. When these cells were transplanted with unsorted cells, they
could form both bone and cartilage. Blocking VEGF signaling promoted chondrogenesis. Subcutaneous implantation of BMP2 in a collagen sponge in mouse inguinal
pad formed ectopic bone; however, it did not originate from circulating SSCs recruited
to implanted sites but SSCs formation was induced in the adipose tissue. It is not clear
whether the CD105+ or CD105- population of adipose tissue contributed to SSCs
formation and this ectopic bone formation. Co-delivery of BMP2 with VEGF inhibitor
into adipose tissue favored cartilage formation over bone[128]. We have shown that
the crosstalk between BMP and VEGF signaling pathways enhances osteogenic differentiation of hADSCs through the p38 signaling pathway. Mineralization was
abrogated when the p38 signaling pathway was inhibited[129]. We also found that
VEGF could crosstalk with a downstream signal mediator of BMP, LIM mineralization
protein 1 (LMP1) to enhance cell mineralization and ectopic bone formation mediated
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by osteoprogenitors[130]. Similar to mSSCs, human skeletal stem cells (hSSCs)
formation has also been reported, by the discoverers of mSSCs, in BMP2 treated
adipose tissue. hSSCs displayed the phenotype PDPN+CD73+CD164+CD146-[131].

CD271
CD34+CD271 + hADSCs showed increased osteogenic differentiation compared to
CD34+CD271- and SVF whereas adipogenic and chondrogenic differentiation were
similar[132].

CXCR4
FACS purified CD146+CD31−CD45− hADSCs isolated from different origins such as the
periosteum, adipose, and dermal tissue display different degrees of osteogenic
capabilities. Periosteal cells also express standard adult stem cell markers (CD105,
CD90, CD73), Gli1, PDGRFα, and CXCR4; and are known to be more osteogenic in
vitro as well as in vivo unlike soft tissue-derived CD146+CD31-CD45- ADSCs. Inhibition
of CXCR4 expression abolishes the ability of these ADSCs to induce ectopic bone
formation. Unsorted ADSCs as well as CD146+ ADSCs further selected for CXCR4+
show enhanced osteogenic potential in vitro and in vivo[133].

PDGFRΑ
PDGFRα+CD34 +, PDGFRα+CD34 −, PDGFRα−CD34 +, and PDGFRα−CD34 − were sorted
from SVF of mouse adipose tissue from PDGFRα+CreER and PDGFRα-CreER mice. The
authors found that PDGFRα+CD34+ ADSCs displayed more osteogenic potential in
vitro. They also found that subcutaneously implantation of PDGFRα+ cells and
subcutaneous implantation of BMP2 into inguinal fat pads of PDGFRα-CreER mice
formed more bone as compared to controls[134].

CD105 AND SSEA3 EXPRESSING MUSE CELLS
Multilineage-differentiating stress-enduring (Muse) cells were first identified from
bone marrow, which are of interest. These cells are positive for mesenchymal and
embryonic stem cell markers CD105 and SSEA3. Muse cells comprise a small
population of MSCs in BM-MSCs (1%-2%) and ADSCs (5%). 250000-500000 cells can be
obtained from one gram of lipoaspirate. Adipose-derived Muse cells spontaneously
differentiate into all three germ layers: mesodermal, endodermal, and ectodermal cell
lineages and have non-tumorigenic and immunomodulatory properties. Muse cells
have been successfully used for regeneration of skin, muscle, liver, kidney in different
animal disease models however it has not been tested for its osteogenic differentiation
potential[135].
Thus, the selection of subpopulations of ADSCs can harness abundantly available
ADSCs for applications in bone regeneration.

CONCLUSION
The safety of ADSCs is reasonably established since they have been tested in 79 clinical
trials including 580 patients total and there have been no serious adverse events
reported. However, the clinical trials, as well as the pre-clinical studies investigating
the potential of ADSCs in enhancing bone regeneration, have given confounding
outcomes. In some cases, they were reported to enhance bone healing whereas, in
others, they have failed to do so. It is also difficult to compare outcomes of different
studies as investigators have used different animal models, delivery methods, and
genetic manipulation of ADSCs. In many of the pre-clinical studies, T cell-deficient
hosts were used. This transplant scenario is unlikely to provide a realistic picture of
the osteogenic potential of ADSCs since T cells are likely to modulate bone
regeneration induced by exogenously added adult stem cells. After careful review of
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all the published reports, it is safe to conclude that ADSCs in their unaltered and
unpurified form cannot be considered as reliable therapy for bone repair yet. Two
major steps can be taken to solve this problem - first is to develop potency assays for
each batch of ADSCs used in clinical and pre-clinical studies to allow comparison of
outcomes of different studies and second is to search for a unique and reliable set of
surface markers to define ADSCs. The current definition of adult stem cells can no
longer be applied to ADSCs since both CD105- as well as CD105+ fractions of ADSCs
have been shown to possess bone forming potential. Surface markers such as CD146,
AlphaV, CD200, PDPN, CD164, CXCR4, and PDGFRα will play an important role in
defining osteogenic population within ADSCs in coming years. Areas such as the role
of endogenous bone-progenitors in bone regeneration induced by exogenously added
ADSCs and BMP-responsiveness of ADSCs also need immediate attention. Most of the
studies published so far have not evaluated the survival and differentiation of
transplanted ADSCs as well as recruitment of endogenous bone-progenitors to
investigate whether the regenerated bone is donor stem cells-derived or originates
from endogenous precursors. While BMPs are thought to promote differentiation of
stem cells into the osteogenic lineage and BMP-overexpression has increased boneforming potential of ADSCs in certain animal models, some investigators have also
reported that ADSCs do not respond to BMPs. This observation and recent findings
that implantation of BMP in adipose stroma leads to skeletal reprogramming and de
novo formation of skeletal stem cells in adipose tissue, together, demand urgent
attention of the scientific community to signaling pathways of ADSCs during
osteogenic differentiation and after BMP stimulation. VEGF, BMP and TGF-β signaling
pathways are the most important ones in this regard. Although the current clinically
tested ADSC therapies do not yet appear to induce bone repair reliably, the ADSC
optimizations described in this manuscript, based on cell subset purification and
stimulus/activation, show great promise, and could potentially dominate stem cellbased therapies such as bone regeneration in the future.
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